Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
暂无分享,去创建一个
M. Griesshammer | S. Verstovsek | M. Hino | R. Mesa | A. Vannucchi | V. Rosti | F. Passamonti | C. Harrison | K. Kirito | Carole B. Miller | F. Pane | T. Masszi | E. Rumi | M. Laughlin | S. Durrant | C. Besses | T. Dong | P. Zachée | J. Kiladjian | I. Blau | A. Varela | Nathalie Francillard